Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about IL: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
Interleukin-1 beta (IL-1β) is a potent pro-inflammatory cytokine that plays a central role in the innate immune response and neuroinflammation.
No AI portrait yet
| Gene Symbol | IL |
| Full Name | 18 - Interleukin-18 |
| Chromosome | 11q22.2. |
| Function | Interleukin-1 beta (IL-1β) is a potent pro-inflammatory cytokine that plays a central role in the innate immune response and neuroinflammation. |
| GeneCards | IL |
| Human Protein Atlas | IL |
| Pro-inflammatory cytokines | TNF-α, IL-1β |
| Oxidative stress | ROS, mitochondrial dysfunction |
| Elevated levels | IL-18 is significantly elevated in CSF and plasma of AD patients compared to healthy controls |
| Disease correlation | Levels correlate with cognitive decline measured by MMSE and CDR |
| Pathology association | Associated with amyloid-β plaque deposition and tau hyperphosphorylation |
| Conversion prediction | Elevated IL-18 predicts conversion from mild cognitive impairment (MCI) to AD |
| Mechanistic role | Drives neuroinflammation and synaptic dysfunction |
| Therapeutic target | IL-18 neutralization reduces pathology in AD mouse models |
| CSF and serum elevation | Increased IL-18 in CSF and serum of PD patients |
| Associated Diseases | CRC |
| KG Connections | 1 knowledge graph edges |
| Databases | GeneCardsUniProtNCBI GeneHPASTRING |
Knowledge base pages for this entity
graph TD
N1["🔬 IL"]
N2["CRC"]
N1 -->|"associated with"| N2
style N1 fill:#1a237e,stroke:#7c4dff,stroke-width:3px,color:#e0e0e0| Target | Relation | Type | Str |
|---|---|---|---|
| CRC | associated_with | disease | 0.70 |
| Source | Relation | Type | Str |
|---|---|---|---|
| No incoming edges | |||
Hypotheses where this entity is a therapeutic target
Scientific analyses that reference this entity
neurodegeneration | 2026-04-16 | 2 hypotheses Top: 0.933
neurodegeneration | 2026-04-16 | 7 hypotheses Top: 0.919
neuroinflammation | 2026-04-13 | 2 hypotheses Top: 0.806
clinical neurology | 2026-04-08 | 0 hypotheses
neurodegeneration | 2026-04-04 | 0 hypotheses
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| Plant-based dietary patterns and Alzheimer's disease risk in multiethn | clinical | Alzheimer's disease and relate | 0.950 | 0.00 | human patients | proposed | N/A |
| SIRPα modulation in mouse models of Alzheimer's disease | validation | Alzheimer's disease | 0.900 | 0.00 | mouse models of Alzheimer's di | proposed | N/A |
| NAD depletion effects on monocyte/macrophage differentiation | exploratory | Inflammatory bowel disease | 0.900 | 0.00 | Primary mouse and human monocy | proposed | N/A |
| FK866 treatment in DSS-induced colitis mouse model | validation | Inflammatory bowel disease (co | 0.900 | 0.00 | DSS-induced colitis mice | proposed | N/A |
| Autophagy receptor identification for stress granule elimination | exploratory | neurodegenerative diseases | 0.900 | 0.00 | cultured cells under arsenite | proposed | N/A |
| Synaptic plasticity and protein expression analysis in mPFC | exploratory | insomnia-anxiety comorbidity | 0.850 | 0.00 | mPFC brain slices from PCPA-tr | proposed | N/A |
| FK866 in azoxymethane/DSS colitis-associated cancer model | validation | Colitis-associated cancer | 0.850 | 0.00 | AOM/DSS-treated mice | proposed | N/A |
| FK866 mechanism validation in Rag1-/- mice | validation | Inflammatory bowel disease | 0.850 | 0.00 | Rag1-/- mice with DSS-induced | proposed | N/A |
| Microglial SIRPα expression in human Alzheimer's disease tissue | exploratory | Alzheimer's disease | 0.800 | 0.00 | human brain tissue | proposed | N/A |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| No papers found | ||||
Multi-agent debates referencing this entity
closed · Rounds: 4 · Score: 0.76 · 2026-04-23
closed · Rounds: 4 · Score: 0.76 · 2026-04-16
closed · Rounds: 7 · Score: 0.87 · 2026-04-16
closed · Rounds: 4 · Score: 0.79 · 2026-04-13
closed · Rounds: 4 · Score: 0.76 · 2026-04-12
closed · Rounds: 4 · Score: 0.78 · 2026-04-12
closed · Rounds: 4 · Score: 0.50 · 2026-04-11
closed · Rounds: 4 · Score: 0.79 · 2026-04-09
closed · Rounds: 4 · Score: 0.90 · 2026-04-06
closed · Rounds: 2 · Score: 0.95 · 2026-04-04
Hypotheses and analyses mentioning IL in their description or question text
Score: 0.858 · neurodegeneration · 2026-04-16
## Mechanistic Overview TREM2 R47H Variant-Driven Metabolic Dysfunction as the Primary Trigger for Failed DAM Transition
Score: 0.846 · Alzheimer's disease · 2026-04-07
## Mechanistic Overview Optogenetic viral vector delivery via tFUS-mediated blood-brain barrier opening to restore hippo
Score: 0.845 · Alzheimer's disease · 2026-04-07
## Mechanistic Overview Optogenetic restoration of hippocampal gamma oscillations via selective SST interneuron activati
Score: 0.843 · molecular neurobiology · 2026-04-17
## Mechanistic Overview Gamma Oscillation Entrainment Enhances lncRNA-9969-Mediated Autophagy Through PV Interneuron-Spe
Score: 0.838 · neurodegeneration · 2026-04-17
## Mechanistic Overview Gamma Oscillation Enhancement Synergy starts from the claim that modulating not yet specified wi
Score: 0.827 · Alzheimer's disease · 2026-04-16
## Mechanistic Overview Closed-loop transcranial focused ultrasound to restore hippocampal gamma oscillations via glymph
Score: 0.819 · translational neuroscience · 2026-04-16
## Mechanistic Overview Ketone Utilization Index as Metabolic Flexibility Biomarker starts from the claim that modulatin
Score: 0.811 · neurodegeneration · 2026-04-16
## Mechanistic Overview CLU/APOE Duality in Amyloid Clearance Determines Cell-Type-Specific Vulnerability Thresholds sta
Score: 0.806 · unknown disease · 2026-04-16
## Mechanistic Overview Neutrophil Extracellular Trap (NET) Inhibition starts from the claim that modulating PADI4 withi
Score: 0.806 · neuroinflammation · 2026-04-13
## Mechanistic Overview IL-6 Trans-Signaling Blockade at the Oligodendrocyte-Microglia Interface starts from the claim t
Score: 0.790 · neurodegeneration · 2026-04-24
The most supported model is that pathogenic G2019S shifts the basal catalytic set-point upward, producing higher baselin
Score: 0.784 · neurodegeneration · 2026-04-02
## Mechanistic Overview Competitive APOE4 Domain Stabilization Peptides starts from the claim that modulating APOE withi
Score: 0.778 · neurodegeneration · 2026-04-16
## Mechanistic Overview SIRT1/PGC-1α Axis Activation to Preserve Mitochondrial Resiliency Against Microbiome-Induced Neu
Score: 0.770 · Alzheimer's Disease · 2026-04-05
## Mechanistic Overview LPCAT3-Mediated Lands Cycle Amplification of Ferroptotic Vulnerability in Disease-Associated Mic
Score: 0.768 · neurodegeneration · 2026-04-02
## Mechanistic Overview Chromatin Accessibility Restoration via BRD4 Modulation starts from the claim that modulating BR